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Background and Aims: Angiotensin-converting enzyme II (ACE2) is the key molecule
for understanding the pathophysiology of COVID-19. The risk of COVID-19 and impact
of immunosuppressive treatment on disease course in patients with inflammatory bowel
disease (IBD) remain controversial. We aimed to determine the change of intestinal ACE2
expression before and after biologics treatment including anti-tumor necrosis factor α
(anti-TNFα), anti-integrin, and anti-interleukin (IL)12/23 in IBD patients.
Methods: We analyzed the ACE2 expression through the public database of paired
intestinal biopsies from IBD patients before and after biologic therapy. Change of ACE2
RNA and protein expression were validated in two independent cohorts (Birmingham
cohort and Guangzhou cohort). The correlation between ACE2 expression and disease
activity was also analyzed.
Results: Mining information from the GEO database showed that compared with healthy
control, intestinal ACE2 expression was downregulated in ileum of CD patients, while
upregulated in colon of both CD and UC patients. Colonic ACE2 RNA expression was
decreased significantly in patients responding to anti-TNFα but not anti-integrin and
anti-IL12/23, which was validated in the Birmingham cohort. Using the Guangzhou
cohort including 53 patients matched by pre- and post-anti-TNFα therapy, colonic
ACE2 protein expression was significantly downregulated after anti-TNFα treatment in
responders (P < 0.001) rather than non-responders. Colonic ACE2 expression was
significantly higher in patients with severe histologically active disease compared with
those with moderate (P < 0.0001) and mild (P = 0.0002) histologically active disease.
Conclusion: Intestinal inflammation influences the expression of intestinal ACE2 in IBD
patients, with different alterations in the ileum and colon. Colonic ACE2 expression was
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downregulated after anti-TNFα therapy in IBD patients responding to treatment. This
might provide new clues regarding the risk of SARS-CoV-2 infection and the potential
benefit of sustaining anti-TNFα treatment in patients with IBD.
Keywords: COVID-19, ACE2, inflammatory bowel disease, intestine, anti-TNFα
INTRODUCTION
The outbreak of coronavirus disease 2019 (COVID-19), caused
by severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), has widely spread around the world. Angiotensin-
converting enzyme II (ACE2) has emerged as a key molecule in
the pathophysiology of COVID-19 (1). ACE2 is expressed in the
respiratory tract as well as gastrointestinal tract (2, 3). Emerging
data (4–7) showed that the SARS-CoV-2 may actively infect and
replicate in the human gut enterocytes or organoids andmight be
transmitted via fecal-oral transmission.
Given the use of immunosuppressive agents as well as
malnutrition status, patients with inflammatory bowel disease
(IBD) are generally at increased risk of infection. Unexpectedly,
current epidemiology of SARS-CoV-2 infection in IBD patients,
including published reports from China (8), Spain (9), Italy (10,
11), and the global data from the SECURE-IBD registry (https://
covidibd.org/) (12), did not support a higher risk of COVID-19
in IBD patients compared to that in the general population.
Similar immune signatures in IBD and COVID-19 indicate
that medications of IBD may play a potential role in the
treatment of COVID-19. Some studies supported that infliximab
downregulated ACE2 expression in colon tissue of IBD (13, 14).
Another recent study has showed that biologics and steroids
are linked to the significantly lower expression of ACE2 in
intestinal lamina propria CD11b-enriched cells (15). However,
to our knowledge, few studies have investigated the influence
of biologics on ACE2 expression in gut enterocytes which are
directly exposed to the virus. Our study identified the ACE2
expression with the public database and then validated RNA and
protein expression using clinical samples from two independent
cohorts including China and the UK aiming to determine the
alter expression of intestinal ACE2 especially in enterocytes
before and after biologic therapy including anti-tumor necrosis
factor α (anti-TNFα), anti-integrin and anti-interleukin (IL)
12/23 in IBD patients.
METHODS
Transcriptomic Change of Intestinal ACE2
Pre- and Post-biologic Therapy From the
Gene Expression Omnibus (GEO) Database
We searched the gene expression data sets regarding biologics
in IBD in the GEO database (http://www.ncbi.nlm.nih.gov/
geo/) with the key words “Inflammatory bowel disease/Crohn’s
disease/Ulcerative colitis/IBD/CD/UC,” “intestine/tissue” and
“Homo sapiens.” The inclusion criteria from the data sets were:
(1) intestinal tissue from patients with IBD; (2) paired samples
were collected before and after various biologics and small
molecule inhibitors therapy including but not limited to anti-
TNFα, anti-integrin, and anti-IL12/23; (3) therapeutic efficacy
(i.e., response or not) of each patient was described; (4) the
number of samples per group was not<12 (16). We extracted the
expression value of ACE2 and used two-class paired or unpaired
analyses according to experimental design. Value distributions
were evaluated.
Validation of Intestinal ACE2 RNA
Expression Change by Real-Time
Quantitative Polymerase Chain Reaction
(RT-qPCR) Pre- and Post-anti-TNFα
Therapy
This validation was conducted in a cohort at the University
of Birmingham, UK. Colonoscopy-confirmed active UC and
CD patients were recruited prior to initiation of anti-TNFα
(Infliximab [IFX] or adalimumab [ADA]) therapy. Institutional
research ethics approval was obtained for the study and all
patients had signed informed consent.
Colonoscopic biopsies were taken from the inflamed
segments of IBD patients (UC and CD) before and 12–16
weeks after starting treatment with biologics. The endoscopic
response was judged by Mayo endoscopic score 0–1 or Simple
Endoscopic Score-CD decrease of 50% or greater at week
12–16 compared to baseline (17). Biopsies were transferred
immediately to “RNA later” upon collection and stored at 4◦C
prior to lysis and gentleMACS homogenization (Miltenyi Biotec)
followed by RNeasy on-column RNA extraction and purification
(Qiagen). RNA was quantified by Qubit (Life Technologies)
and 1.5 µg reverse transcribed using iScript reagents (Bio-
Rad). Expression of ACE2 receptor relative to 18SrRNA
was measured by qPCR using Taqman reverse transcription
gene-assays (18SrRNA: 4319413E. ACE2: Hs01085333_m1)
(Life Technologies). Reactions were performed in triplicate as
singleplex assays and expression of ACE2 relative to 18SrRNA
calculated by 106(2−dCt). The expression change between pre-
and post-treatment was tested.
Validation of Intestinal ACE2 Protein
Expression Change Using
Immunohistochemistry (IHC) Assays Pre-
and Post-anti-TNFα Treatment
To determine the protein expression of ACE2 in the intestinal
epithelial cells, patients with CD receiving anti-TNFα treatment
were included from the First Affiliated Hospital of Sun Yat-
sen University, Guangzhou, China. All patients underwent
colonoscopy by gastroenterologists with more than 5 years of
experience in IBD before and 12–14 weeks after anti-TNFα
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treatment, and all biopsies were taken from inflamed gut
segments. Institutional research ethics approval was obtained for
the study.
IHC was performed using paraffin-embedded tissues from
intestinal mucosal biopsies obtained during endoscopy from
the IBD patients mentioned above. Tissue sections were
deparaffinized in xylene and hydrated through a graded series
of alcohol to tap water. Antigen was retrieved in citrate buffer
for 20min and cooled to room temperature. The sections were
incubated with 3% H2O2 in distilled water for 15min. After
being rinsed three times with phosphate-buffered saline (PBS),
the sections were incubated with rabbit polyclonal IgG primary
antibodies against ACE2 (1:500 dilution, ab15348; Abcam; USA)
overnight at 4◦C. Then, the sections were incubated with the
secondary antibody (1:50000, ab205718; Abcam; USA) for 30min
at room temperature, followed by two times 5min washing with
PBS. Finally, the sections were stained with hematoxylin. The
protein expression of ACE2 was evaluated in a random and
blinded fashion and was assigned an IHC score, which was based
on the approximate percentage of positively stained cells over
overall intestinal epithelial cells (ranging from 0 to 100%), as
described in previously published methods (18).
Assessment of Disease Activity and
Definition of Outcome
The disease activity of the CD patients from the China cohort
was analyzed using endoscopic and histologic assessment. The
Crohn’s Disease Endoscopic Index of Severity (CDEIS) score
was used for endoscopic scoring. Consistent with the STRIDE
guidelines (17), a decrease by >5 or at least 50% from baseline
in CDEIS demonstrates endoscopic response. A semiquantitative
evaluation for endoscopic disease activity was given as follows:
CDEIS<3 suggested inactive, 3–8mildly active, 9–12moderately
active, and >12 severely active (19).
Histological disease activity was assessed by a blinded IBD
experienced pathologist in random order. The modified Global
Histologic Disease Activity Score (mGHAS) (20, 21) was used
and the histologic response was defined as modified GHAS ≤4
in those patients with baseline score >4. A semiquantitative
evaluation for histological disease activity was given as follows:
inactive, 0; mildly active, 1–5; moderately active, 6 −10; and
severely active, 11–14.
Statistical Analysis
The original expression data was collected and then plotted
by GraphPad Prism 8 (GraphPad Software, La Jolla, CA).
All statistical analyses were performed IBM SPSS Statistics
25.0 software package (IBM, Armonk, NY, USA). Continuous
variables were summarized as medians and interquartile ranges
(IQRs). The Student’s t-test or analysis of variance (ANOVA) test
was used for parametric tests, while the Wilcoxon signed-rank
test or Kruskal-Wallis test was performed for non-parametric
tests. The Spearman correlation was used to evaluate the
relationship of IHC score and endoscopic or histological disease
activity score. All statistical testing was two-sided, and P <
0.05 was considered significant and indicated as follows: ns, not
significant; ∗P ≤ 0.05; ∗∗P ≤ 0.01; ∗∗∗P ≤ 0.001; ∗∗∗∗P ≤ 0.0001.
RESULTS
Intestinal ACE2 Expression in GEO
Database
Five GEO datasets [GSE16879 (22), GSE23597 (23), GSE92415
(24), GSE73661 (25), and GSE112366 (26)] were included in
the final analysis. Detailed information for datasets included
was summarized in Table 1. Compared with healthy control,
intestinal ACE2 expression was downregulated in ileum
of CD patients (GSE16879), while upregulated in colon
of both CD and UC patients (GSE16879, GSE92415, and
GSE73661), significantly.
As shown in Figures 1A–C, ACE2 expression in colon tissue
was decreased significantly in patients responding to anti-
TNFα (except GSE23597). On the contrary, ACE2 in ileum
tissue was upregulated significantly in CD patients using anti-
TNFα regardless of the response status (GSE16879). Intestinal
ACE2 expression did not decrease after VDZ or UST treatment
(Figures 1D,E).
Colonic ACE2 RNA Expression Was
Downregulated in IBD Patients
Responding to anti-TNFα
In the UK cohort, we studied 24 IBD patients (11CD, 13
UC) initiating biologic therapies (CD 8 ADA, 2 IFX, 1 UST;
UC 5 ADA, 4 IFX, 4 VDZ). The baseline characteristics of
patients are shown in Table 2. Figure 1F shows a statistically
significant decrease in colonic expression of ACE2 in responders
(n = 11) to anti-TNFα (P = 0.0250). Non-responders to anti-
TNFα (4 UC, 1CD) did not exhibit any significant decrease in
ACE2 expression. Patients treated with VDZ did not show any
significant decrease in ACE2 expression.
Colonic ACE2 Protein Expression Was
Downregulated in CD Patients Responding
to anti-TNFα
In the China cohort, we included 66CD patients for IHC
validation and found 53 patients matched by pre- and
post-anti-TNFα therapy (Supplementary Table 1). The baseline
characteristics of patients are shown in Table 2. As demonstrated
in Figure 2A, in both endoscopic and histologic assessments,
ACE2 expression was significantly downregulated in colonic
biopsy after anti-TNFα treatment in responders (P < 0.001)
rather than non-responders (the representative IHC images are
shown in Figure 2D). Besides, ACE2 protein expression in ileum
increased after anti-TNFα treatment in responders (n= 3). There
was no difference in ACE2 protein expression in colon or ileum
of non-responders.
Colonic ACE2 Protein Expression
Positively Correlated With Disease Activity
We studied 147 specimens with different disease activity from
total CD patients of the China cohort. Colonic ACE2 expression
was significantly higher in patients with severe histologically
active disease compared with those with moderate (P < 0.0001)
and mild (P = 0.0002) histologically active disease. Ileal ACE2




























TABLE 1 | Summary of included GEO datasets.
Patients Cohort Healthy
Control









































































No colon weeks 0, 6 Endoscopic
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GLM GSE92415


























Yes ileum weeks 0, 8,
44
CDAI score UST GSE112366
aDisease subtypes are classified according to Montreal classification; bResponders/non-responders pair, one pair means that the patient has biopsy samples before and after treatment; cStudy time point, time to definite response
status; dDefinition of outcome, Method to definite response/non-response after treatment.
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FIGURE 1 | The relative ACE2 mRNA expression level of intestinal mucosal biopsy specimens before and after biologic therapy with anti-TNFα (infliximab/IFX, A,C;
golimumab/GLM, B), vedolizumab/VDZ (D) or ustekinumab/UST (E) in patients with CD (A,E) or UC (B–D) from GEO data sets. (F) RT-qPCR data of the intestinal
mucosal ACE2 expression in IBD responders before and after anti-TNFα therapy. In the matched comparison (A,C–F), lines between two samples represent the
change in ACE2 expression before and after treatment for one patient. In the unpaired comparison (B), mean and range are shown in the scatterplot. There was not
statistical difference between the IBD patients before and after therapy. ns, not significant; *P < 0.05; ***P < 0.001 (in patients after vs. before therapy). #P < 0.05;
###P < 0.001 (in healthy controls vs. patients before therapy).
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TABLE 2 | Baseline characteristics of patients with inflammatory bowel disease





No. of patients 66 24
Male, N (%) 43 (65.2%) 12 (50%)
Age at time of collection (years)
Mean (SD) 23.4 (8.9) 42.0 (12.6)
Range 10–46 24–63
Duration of disease (months)
Mean 44.7 (55.8) 121.0 (106.0)
Range 1–366 6–372
Crohn’s Disease (CD), N 66 11
Location, N
L1, Ileal 5 4
L2, Colonic 3 5
L3, Ileocolonic 58 2
Disease behavior, N
B1, Non-stricturing, non-penetrating 39 6
B2, Stricturing 19 3
B3, Penetrating 8 2
Ulcerative Colitis (UC), N 0 13
Proctitis (E1) 0 1
Left sided (E2) 0 5
Extensive (E3) 0 7
Biologics commenced, N
Anti-TNF 66 (all CD) 19 (10CD, 9 UC)
Vedolizumab 0 4 (all UC)
Ustekinumab 0 1 (CD)
expression was comparable among different disease activity
groups.When stratifying the disease activity by endoscopic score,
no significant difference existed among disease activity groups
(Figure 2B).
As is shown in Figure 2C, ACE2 expression positively but
weakly correlated with histological disease activity (ρ = 0.3357,
95% confidence interval [CI] 0.1502 to 0.4983, P = 0.0004) and
endoscopic disease activity (ρ = 0.1881, 95% CI−0.0105–0.3723,
P = 0.0559) in colon, while no correlation existed between ileal
ACE2 expression and histological or endoscopic disease activity.
DISCUSSION
There are controversies about the risk of SARS-CoV-2 infection
in patients with IBD (27). It was reported that the soluble form
of ACE2, which acts as a competitive binding partner for SARS-
CoV-2, is up-regulated in the peripheral blood of IBD patients
and then limits SARS-CoV-2 infection (28, 29). Several studies
showed that IBD medications especially biologics could regulate
the intestinal ACE2 expression of IBD (13–15). However, few
studies have directly investigated the influence of biologics on
ACE2 expression in gut enterocytes which are directly exposed
to the virus. The two recent landmark studies (6, 7) have
confirmed that SARS-CoV-2 could productively infect human
gut enterocytes and intestinal organoids. In our study, we found
that IBD patients had a higher expression of ACE2 in colon
tissue while lower in ileum tissue vs. healthy control, which
was consistent with the published data (13). Additionally, our
result showed that the expression of colonic epithelial ACE2 was
downregulated in IBD patients responding to anti-TNFα therapy,
using GEO data analysis and then validated with qPCR and IHC
assays. These results might provide new evidence and knowledge
to the risk of SARS-CoV-2 infection in patients with IBD using
different medications and the potential role of anti-TNFα in the
treatment of COVID 19.
Our study demonstrated that intestinal epithelial ACE2
expression increased with more severe disease activity, which
may be due to the higher inflammatory cytokines. Previous
studies (30, 31) showed that ACE2 is increased in human
bronchial epithelial cells infected by SARS-CoV-2 as a response to
inflammatory cytokine stimulation including interferon (IFN)-
γ. Several inflammatory cytokines like IFN-γ, TNFα, IL-1,
and IL-6 could be upregulated in active IBD patients (28).
In addition, ACE2 expression was downregulated after anti-
TNFα therapy only in responders rather than non-responders.
In the registered IBD patients with COVID-19 from SECURE-
IBD (12), there were 762 patients with anti-TNFα therapy
alone, 651 (85%) of whom recovered without hospital admission
and four patients died in total. On the contrary, 65% of 773
patients with treatment of sulfasalazine/mesalamine recovered
without hospital admission and 37 patients died. These data
indicated that IBD patients with anti-TNFα treatment might
have a better outcome of COVID than other medications (32).
The potential explanations may have three points: (1) anti-
TNFα treatment downregulated IFN-γ which would induced
the expression of ACE2 through downregulating IFN-γ (32); (2)
anti-TNFα treatment also downregulated other proinflammatory
cytokines in “TNF dependent cytokine cascade,” such as IL-1, IL-
6 and IFN-γ which also play important roles in cytokine storm
syndrome in COVID-19 (32); (3) anti-TNFα could induce a
reduction in leucocyte trafficking due to reduction of adhesion
molecules, vascular endothelial growth factor and chemokines in
both IBD and COVID-19 (33, 34). Indeed, an urgent demand
for clinical trials of anti-TNFα therapy for COVID-19 has been
proposed recently (35). Moreover, the clinical trial of anti-
TNFα in treating COVID-19 (ChiCTR2000030089) is ongoing.
Future studies investigating the protective role of anti-TNFα for
IBD or COVID 19 patients during the COVID-19 pandemic
are warranted.
Except for the regulation of inflammatory cytokines, ACE2
may participate in intestinal stem cell proliferation, mucosal
healing and crypt pathology in the pathogenesis of IBD. ACE2
plays an important role in the endothelial repair in acute lung
injury (36) and the healing of gastric ulcers (37), potentially
through reducing Angiotensin (Ang) II and increasing the
production of Ang 1–7. A recent study (38) proposed that
ACE2 contributed to the proliferation of intestinal stem cells and
the maintenance of epithelial barrier function in DSS-induced
colitis mice. ACE2-deficient mice developed increased intestinal
epithelial injury associated with crypt damage compared to the
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FIGURE 2 | The relative ACE2 protein expression in intestinal mucosal biopsy specimens from patients with CD by Immunohistochemistry assays. The expression
level was measured by percentage of positively stained cells. The sample sizes of each group are shown in Supplementary Table 1. (A) ACE2 expression before and
after anti-TNFα treatment (matched comparison). (B) ACE2 expression among different disease activity groups defined by endoscopic and histological assessment.
Median and interquartile range are shown in the scatterplot. (C) Spearman rank correlation analysis between ACE2 expression of colonic epithelial cells and
endoscopic or histological disease activity. (D) Representative images (immunohistochemical staining for ACE2) of the colonic biopsy specimens before and after
anti-TNFα treatment. (a–c) Biopsy before treatment. The histological score is 6. The percentage staining of ACE2 in colonic epithelial cells is 80%. (d–f) Biopsy after
treatment. The histological score is 1. The percentage staining of ACE2 in colonic epithelial cells is 20%. All scale bars are 100µm. ns, not significant; **P < 0.01; ***P
< 0.001, ****P < 0.0001.
Frontiers in Medicine | www.frontiersin.org 7 January 2021 | Volume 7 | Article 613475
Li et al. Biologics and Intestinal ACE2 Expression
wild-typemice (39). However, there have been debates on the role
of ACE2 in IBD. It is also reported that an ACE2 inhibitor may
have an anti-inflammatory effect in DSS-induced colitis mice
(40). Considering the dual role of ACE2 in the development of
colitis, it warrants further study.
In the current study, a significant difference of ACE2
expression was found in responders rather than non-responders
to anti-TNFα in IBD patients with colonic involvement, which
was validated with IHC assays of CD patients in China cohort
(Figure 2A). There are two patients with significant changes
of ACE2, whose endoscopic and histological scores post-
treatment are both close to zero. It demonstrated that the ACE2
may play an important role in the anti-TNFα mediated anti-
inflammatory pathways in colonic CD. The difference was still
statistically significant when taking out these two patients. Anti-
TNFα is the mainstay of CD treatment. Nonetheless, around
one-third of CD patients experience a loss of response (41).
Besides, ACE2 or renin-angiotensin system (RAS) has been
demonstrated to influence the inflammation and fibrosis in IBD
(18). Thus, whether ACE2 or RAS could help for predicting
response to anti-TNFα treatment deserves more research. It is
unclear whether the concomitant medication influence ACE2
expression. In the present study, of 53 patients with intestinal
biopsies pre- and post-anti-TNF therapy, none of them were
on concomitant steroid use, and only one patient was on
recent methylprednisolone use before anti-TNF therapy. There
were 45 patients who received combination therapy of anti-
TNF with azathioprine (Supplementary Table 2), most of whom
had treatment failure of azathioprine before accelerating anti-
TNF therapy. We further performed a subgroup analysis of
patients on anti-TNF and azathioprine therapy and came to the
same conclusion that colonic ACE2 was decreased significantly
in patients responding to anti-TNFα (endoscopic response, P
= 0.0096; histologic response, P = 0.0039). In recent studies
(14, 32), international data from SECURE-IBD highlighted
the association of corticosteroids with adverse COVID-19
outcomes and the probable safety of anti-TNF. The association
between monotherapy or combination therapies and the risk
of COVID-19 has been explored in some observational studies
(14, 32, 42). Our study used paired samples before and after
anti-TNF therapy, which could minimize the inter-individual
differences such as concomitant medication. However, some
confounding factors are inevitable in our current retrospective
study. Further prospective well-designed studies are needed to
validate our results.
Our study also showed that anti-TNFα could downregulate
the ACE2 expression level in colon of patients with IBD rather
than in ileum. ACE2 in ileum tissue was upregulated significantly
in CD patients using anti-TNFα regardless of the response
status (GSE16879, Figure 1A), which demonstrated that anti-
TNFα may not influence the ileal ACE2 expression. Numerous
previous evidence (43) supported that colonic CD is a different
phenotype from ileal CD at the level of genetics, macroscopic,
cellular immunology, microbiota, and treatment. It is worth
mentioning that isolated ileal disease location has been observed
to be a negative predictor of responses to anti-TNFα therapy in
several cohort studies and there was no significant difference in
efficacy of VDZ treatment in different locations (44). Therefore,
we speculated that the RAS may be an important factor in the
TNF-pathway of colonic CD and UC.
There was a positive correlation between epithelial ACE2
expression and disease activity, and the association was
stronger using histological score compared to endoscopic score.
Endoscopic and clinical measurements are predominately used to
determine response to therapy in IBD. There has been growing
interest in using histological score as measuring disease activity
and treatment outcome. Previous studies (45) have shown that
endoscopic assessment and clinical measures may not adequately
reflect disease activity, whereas histologic measurement is
more sensitive to detect disease activity and predict response
to therapy.
One strength of the present study was that we included the
data of matched intestinal mucosal biopsies from IBD patients
before and after biologic therapy, so participant variables (i.e.,
individual differences) are reduced. Besides, we provided three
sets of data to support our ACE2 expression changes after
biologics use especially the down-regulation after anti-TNFα
treatment and validated in IBD cohorts from different countries.
More importantly, we not only assessed the disease activity
and response by endoscopic score but also histological score
which was better to illustrate the association between intestinal
epithelial ACE2 expression and inflammatory activity.
Several certain limitations also existed. Firstly, because of the
inconvenience of collecting biopsies from patients during the
COVID19 pandemic, the validation of ACE2 mRNA and protein
was conducted in two separate cohorts and a small amount
of ileum tissue was included, which limited the assessment of
the difference in ACE2 expression between terminal ileum and
colon. Besides, we did not include samples for validation of
ACE2 protein expression before and after VDZ/UST treatment,
given these two biologics were not available in China before
2020. Finally, the validation of ACE2 protein expression did not
included UC patients, because there were insufficient numbers
of specimens of UC patients with anti-TNFα treatment to
conduct statistical analysis. Further research is needed to confirm
these findings.
In conclusion, our study showed that colonic ACE2 expression
was downregulated after anti-TNFα therapy in IBD patients
responding to treatment. This might provide new clues regarding
the risk of SARS-CoV-2 infection and the potential benefit of
maintaining anti-TNFα treatment in patients with IBD.
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